{"id":4330,"date":"2026-10-19T21:32:16","date_gmt":"2026-10-20T01:32:16","guid":{"rendered":"https:\/\/canasanta.ca\/?p=4330"},"modified":"2026-10-19T21:47:54","modified_gmt":"2026-10-20T01:47:54","slug":"una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","title":{"rendered":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa"},"content":{"rendered":"<h3><strong>Una p\u00edldora experimental tomada una vez al d\u00eda logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave. El tratamiento todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de fase 3.<\/strong><\/h3>\n<p>&nbsp;<\/p>\n<p>Gilead Sciences inform\u00f3 este 19 de octubre de 2026 resultados positivos del ensayo SWIFT de fase 2 con <strong>emvistegrast (GS-1427)<\/strong>, un inhibidor oral de la integrina \u03b14\u03b27 dise\u00f1ado para tratar la enfermedad inflamatoria intestinal.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>El 66% respondi\u00f3 al tratamiento<\/strong><\/h2>\n<p>Despu\u00e9s de 12 semanas, el <strong>66% de los participantes<\/strong> que recibieron la dosis de 200 mg alcanz\u00f3 respuesta cl\u00ednica, frente al <strong>37% del grupo placebo<\/strong>. El estudio cumpli\u00f3 as\u00ed su objetivo principal.<\/p>\n<p>La diferencia tambi\u00e9n apareci\u00f3 en un indicador m\u00e1s exigente: la remisi\u00f3n cl\u00ednica. La alcanz\u00f3 el <strong>31% de quienes recibieron emvistegrast 200 mg<\/strong>, frente al <strong>8% con placebo<\/strong>. Adem\u00e1s, el 39% mostr\u00f3 mejor\u00eda endosc\u00f3pica frente al 12% del grupo placebo.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Una v\u00eda conocida, pero en forma de p\u00edldora<\/strong><\/h2>\n<p>Emvistegrast bloquea selectivamente la v\u00eda \u03b14\u03b27, un objetivo biol\u00f3gico ya validado en la enfermedad inflamatoria intestinal. La diferencia es que Gilead intenta convertir ese mecanismo en un tratamiento oral de una sola toma diaria, una opci\u00f3n potencialmente m\u00e1s sencilla que algunas terapias avanzadas administradas por otras v\u00edas.<\/p>\n<p>La colitis ulcerosa es una enfermedad inflamatoria cr\u00f3nica del intestino grueso que puede producir dolor abdominal, diarrea, sangrado y periodos recurrentes de actividad y remisi\u00f3n. Aunque existen varios tratamientos avanzados, una parte de los pacientes no consigue un control sostenido de la enfermedad.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Qu\u00e9 se sabe sobre la seguridad<\/strong><\/h2>\n<p>Seg\u00fan los datos comunicados por la compa\u00f1\u00eda, los acontecimientos adversos aparecieron en el 36% de los participantes tratados con emvistegrast y en el 37% de quienes recibieron placebo. Hubo acontecimientos adversos graves en cuatro de los 178 pacientes tratados con distintas dosis del f\u00e1rmaco, pero los investigadores consideraron que ninguno estaba relacionado con el medicamento.<\/p>\n<p>Estos resultados proceden de un ensayo de fase 2 y no equivalen a una aprobaci\u00f3n regulatoria. <strong>Emvistegrast sigue siendo un medicamento experimental<\/strong>: su seguridad y eficacia a\u00fan no han sido establecidas para uso cl\u00ednico general.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>El siguiente paso ser\u00e1 la fase 3<\/strong><\/h2>\n<p>Gilead indic\u00f3 que planea iniciar en 2027 un estudio de fase 3 de emvistegrast como monoterapia. El ensayo SWIFT contin\u00faa, por lo que todav\u00eda se esperan datos adicionales de mantenimiento y seguimiento a m\u00e1s largo plazo.<\/p>\n<p>Los resultados fueron presentados como trabajo de \u00faltima hora durante la United European Gastroenterology Week 2026 en Barcelona. Reuters inform\u00f3 este lunes sobre los datos y el avance del programa cl\u00ednico.<\/p>","protected":false},"excerpt":{"rendered":"<p>Emvistegrast, una terapia oral experimental de Gilead, alcanz\u00f3 respuesta cl\u00ednica en el 66% de los pacientes con colitis ulcerosa moderada o grave frente al 37% con placebo en un ensayo de fase 2.<\/p>","protected":false},"author":284226809,"featured_media":4331,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":true},"categories":[33205457,2127],"tags":[33207109,33207110,33207112,33207172,33207111],"class_list":["post-4330","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-salud","tag-colitis-ulcerosa","tag-emvistegrast","tag-enfermedad-inflamatoria-intestinal","tag-ensayo-clinico-fase-2","tag-gilead-sciences"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa - Ca\u00f1asanta<\/title>\n<meta name=\"description\" content=\"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/health\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa\" \/>\n<meta property=\"og:description\" content=\"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/health\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-20T01:32:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-20T01:47:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa\",\"datePublished\":\"2026-10-20T01:32:16+00:00\",\"dateModified\":\"2026-10-20T01:47:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"keywords\":[\"colitis ulcerosa\",\"emvistegrast\",\"enfermedad inflamatoria intestinal\",\"ensayo cl\u00ednico fase 2\",\"Gilead Sciences\"],\"articleSection\":[\"AL D\u00cdA!\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/\",\"name\":\"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-10-20T01:32:16+00:00\",\"dateModified\":\"2026-10-20T01:47:54+00:00\",\"description\":\"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"width\":1200,\"height\":630,\"caption\":\"Medicamentos en una investigaci\u00f3n cl\u00ednica sobre colitis ulcerosa\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salud\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/salud\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa - Ca\u00f1asanta","description":"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/health\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","og_locale":"en_US","og_type":"article","og_title":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa","og_description":"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.","og_url":"https:\/\/canasanta.ca\/en\/health\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-10-20T01:32:16+00:00","article_modified_time":"2026-10-20T01:47:54+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa","datePublished":"2026-10-20T01:32:16+00:00","dateModified":"2026-10-20T01:47:54+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","keywords":["colitis ulcerosa","emvistegrast","enfermedad inflamatoria intestinal","ensayo cl\u00ednico fase 2","Gilead Sciences"],"articleSection":["AL D\u00cdA!","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","url":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/","name":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","datePublished":"2026-10-20T01:32:16+00:00","dateModified":"2026-10-20T01:47:54+00:00","description":"Emvistegrast, la p\u00edldora experimental de Gilead, logr\u00f3 respuesta cl\u00ednica en 66% de pacientes con colitis ulcerosa frente a 37% con placebo en fase 2.","breadcrumb":{"@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","width":1200,"height":630,"caption":"Medicamentos en una investigaci\u00f3n cl\u00ednica sobre colitis ulcerosa"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/salud\/una-pildora-experimental-de-gilead-logra-respuesta-clinica-en-el-66-de-pacientes-con-colitis-ulcerosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"Salud","item":"https:\/\/canasanta.ca\/category\/salud\/"},{"@type":"ListItem","position":3,"name":"Una p\u00edldora experimental de Gilead logra respuesta cl\u00ednica en el 66% de pacientes con colitis ulcerosa"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-17Q","jetpack-related-posts":[{"id":4199,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-emvistegrast-colitis-ulcerosa-ensayo-fase-2\/","url_meta":{"origin":4330,"position":0},"title":"Una p\u00edldora experimental logra remisi\u00f3n en el 31% de pacientes con colitis ulcerosa en un ensayo","author":"Ca\u00f1asanta","date":"October 22, 2026","format":false,"excerpt":"\u00a0\u00a0Una p\u00edldora experimental de una toma diaria logr\u00f3 una respuesta cl\u00ednica significativamente mayor que el placebo en pacientes con colitis ulcerosa moderada o grave, seg\u00fan resultados de fase 2 anunciados este lunes 19 de octubre por Gilead Sciences. El f\u00e1rmaco, emvistegrast, todav\u00eda no est\u00e1 aprobado y deber\u00e1 superar ensayos de\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"M\u00e9dico conversa con una paciente hospitalizada, imagen editorial para informaci\u00f3n sobre colitis ulcerosa","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Colitis-ulcerosa-%E2%80%94-ensayo-clinico.jpg?fit=1080%2C720&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4044,"url":"https:\/\/canasanta.ca\/en\/salud\/farmaco-experimental-anb033-celiaquia-gluten-intestino\/","url_meta":{"origin":4330,"position":1},"title":"Un f\u00e1rmaco experimental protege el intestino frente al gluten en un ensayo sobre celiaqu\u00eda","author":"Ca\u00f1asanta","date":"October 18, 2026","format":false,"excerpt":"Un peque\u00f1o ensayo cl\u00ednico de fase 1b encontr\u00f3 que ANB033 redujo el da\u00f1o intestinal y los s\u00edntomas durante una exposici\u00f3n controlada al gluten en pacientes con celiaqu\u00eda.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Pan de trigo sobre una tabla, imagen editorial para un art\u00edculo sobre celiaqu\u00eda y un tratamiento experimental","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Gluten-y-celiaquia-%E2%80%94-portada-Canasanta.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4843,"url":"https:\/\/canasanta.ca\/en\/salud\/pildora-experimental-reduce-recaidas-esclerosis-multiple\/","url_meta":{"origin":4330,"position":2},"title":"Una p\u00edldora experimental reduce un 55% las reca\u00eddas de esclerosis m\u00faltiple","author":"Ca\u00f1asanta","date":"October 21, 2026","format":false,"excerpt":"Fenebrutinib, el tratamiento oral experimental de Roche, redujo un 55% las reca\u00eddas de esclerosis m\u00faltiple en ensayos de fase avanzada y mostr\u00f3 efectos sobre la progresi\u00f3n de la enfermedad.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Especialistas m\u00e9dicos examinan im\u00e1genes cerebrales durante una evaluaci\u00f3n neurol\u00f3gica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esclerosis-multiple-%E2%80%94-nuevos-resultados-de-fenebrutinib.jpg?fit=1080%2C608&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4518,"url":"https:\/\/canasanta.ca\/en\/salud\/tezepelumab-remision-esofagitis-eosinofilica\/","url_meta":{"origin":4330,"position":3},"title":"UN F\u00c1RMACO LOGRA 69% DE REMISI\u00d3N EN UNA ENFERMEDAD DEL ES\u00d3FAGO","author":"Ca\u00f1asanta","date":"October 20, 2026","format":false,"excerpt":"Tezepelumab logr\u00f3 remisi\u00f3n histol\u00f3gica en hasta el 68,9% de pacientes con esofagitis eosinof\u00edlica en un ensayo fase 3 y redujo la dificultad para tragar.","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Imagen endosc\u00f3pica de un es\u00f3fago con la estructura anular caracter\u00edstica de la esofagitis eosinof\u00edlica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Esofagitis-eosinofilica-%E2%80%94-endoscopia.jpg?fit=1200%2C933&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1891,"url":"https:\/\/canasanta.ca\/en\/al-dia\/la-inyeccion-que-hace-perder-21-del-peso\/","url_meta":{"origin":4330,"position":4},"title":"THE INJECTION THAT CAUSES YOU TO LOSE 21% OF WEIGHT","author":"Ca\u00f1asanta","date":"September 29, 2026","format":false,"excerpt":"Un nuevo f\u00e1rmaco experimental de Eli Lilly logra una p\u00e9rdida media cercana a 50 libras en pacientes con obesidad y diabetes tipo 2. Los resultados de fase 3 colocan a retatrutide entre los tratamientos para adelgazar m\u00e1s potentes estudiados hasta ahora. Eli Lilly acaba de presentar nuevos resultados de retatrutide,\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"CS inyeccion diabetes001","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_inyeccion_diabetes001.jpg?fit=1200%2C628&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4189,"url":"https:\/\/canasanta.ca\/en\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","url_meta":{"origin":4330,"position":5},"title":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre. El\u2026","rel":"","context":"In &quot;AL D\u00cdA!&quot;","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Laboratorio de investigaci\u00f3n gen\u00e9tica y secuenciaci\u00f3n, imagen editorial sobre terapias siRNA y la adquisici\u00f3n de Silence Therapeutics","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Emvistegrast-y-colitis-ulcerosa.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=4330"}],"version-history":[{"count":4,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4330\/revisions"}],"predecessor-version":[{"id":4343,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4330\/revisions\/4343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/4331"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=4330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=4330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=4330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}